| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2568770 | Toxicology and Applied Pharmacology | 2014 | 11 Pages |
•Betulinic acid reduced PTHrP production in human metastatic breast cancer cells.•Betulinic acid blocked RANKL/OPG ratio in PTHrP-stimulated human osteoblastic cells.•Betulinic acid inhibited RANKL-induced osteoclastogenesis in bone marrow macrophages.•Betulinic acid decreased bone resorption by suppressing osteoclast activity.•Orally administered betulinic acid inhibited cancer-associated bone diseases in mice.
Many breast cancer patients experience bone metastases and suffer skeletal complications. The present study provides evidence on the protective and therapeutic potential of betulinic acid on cancer-associated bone diseases. Betulinic acid is a naturally occurring triterpenoid with the beneficial activity to limit the progression and severity of cancer, diabetes, cardiovascular diseases, atherosclerosis, and obesity. We first investigated its effect on breast cancer cells, osteoblastic cells, and osteoclasts in the vicious cycle of osteolytic bone metastasis. Betulinic acid reduced cell viability and the production of parathyroid hormone-related protein (PTHrP), a major osteolytic factor, in MDA-MB-231 human metastatic breast cancer cells stimulated with or without tumor growth factor-β. Betulinic acid blocked an increase in the receptor activator of nuclear factor-kappa B ligand (RANKL)/osteoprotegerin ratio by downregulating RANKL protein expression in PTHrP-treated human osteoblastic cells. In addition, betulinic acid inhibited RANKL-induced osteoclastogenesis in murine bone marrow macrophages and decreased the production of resorbed area in plates with a bone biomimetic synthetic surface by suppressing the secretion of matrix metalloproteinase (MMP)-2, MMP-9, and cathepsin K in RANKL-induced osteoclasts. Furthermore, oral administration of betulinic acid inhibited bone loss in mice intra-tibially inoculated with breast cancer cells and in ovariectomized mice causing estrogen deprivation, as supported by the restored bone morphometric parameters and serum bone turnover markers. Taken together, these findings suggest that betulinic acid may have the potential to prevent bone loss in patients with bone metastases and cancer treatment-induced estrogen deficiency.
Graphical abstractFigure optionsDownload full-size imageDownload high-quality image (65 K)Download as PowerPoint slide
